Komunikaty PR

Viking Pest Control Reports Twice as Many Spotted Lanternfly Calls to date in from 2024 to 2025

2025-06-16  |  20:55:04
nfographic from Viking Pest Control showing the lifecycle of the Spotted Lanternfly: egg laying (Sep–Dec), eggs (Oct–Jun), hatch and first instar (May–Jun), second instar (Jun–Jul), third instar (Jun–Jul), fourth instar (Jul–Sep), and adult stage (Jul–Sep

Viking Pest Control illustrates the seasonal lifecycle of the invasive Spotted Lanternfly, highlighting key stages from egg laying to adulthood across the calendar year.

The Invasive, Plant-Destroying Pest is Quarantined in Every County in New Jersey

BASKING RIDGE, NJ, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- Spotted Lanternflies, the invasive, plant-destroying, polka-dotted pests that have prompted a statewide quarantine in New Jersey, are once again making their presence known. Viking Pest Control’s total spotted lanternfly call volume has doubled in 2025 compared to the same time frame in 2024. That sharp increase should raise alarms for both homeowners and agricultural experts. If you think you haven’t seen any this season, you might be surprised—they're already here, just not in the form most people recognize.

Why You Might Not Recognize Spotted Lanternfly Nymphs

Most people associate spotted lanternflies with their adult form—those striking black-and-red insects with spotted wings that swarm trees, porches, and backyard gardens in late summer and early fall. But long before they reach their eye-catching adult stage, lanternflies go through several nymph phases, which is what we are getting calls for this spring.

Spotted lanternfly nymphs begin their life as small, black insects with bright white polka dots and no wings. They’re often mistaken for other types of bugs or simply overlooked because of their small size. As they develop, the nymphs transition into a red and black coloration, still wingless but increasingly visible and mobile. It’s during these early stages—when most people aren’t paying close attention—that they begin feeding and causing damage.

Why It’s Critical to Stop Spotted Lanternfly Nymphs Early

While the best time to prevent lanternfly infestations is between fall and early spring—when the insects are dormant in egg masses—the current nymph stage is the next best opportunity to act. Egg masses can be scraped off trees and outdoor surfaces during the colder months, but once they’ve hatched, quick action is needed.

Nymphs, although not as destructive as adult lanternflies, still pose a risk—especially to young and vulnerable plants. They feed on the tender shoots of annuals, perennials, and garden plants, potentially stunting growth or killing off smaller vegetation. If allowed to mature, the nymphs will transform into the highly destructive adults that wreak havoc on hardwood trees, fruit trees, grapevines, and ornamental plants.

Adult lanternflies feed on plant sap using piercing mouthparts, which stresses the host plant. But the damage doesn’t stop there. As they feed, they excrete a sticky substance known as honeydew, which attracts ants and fosters the growth of sooty mold. This black fungus coats leaves and bark, blocking sunlight and further harming the plant. In vineyards, orchards, and hardwood groves, this damage can be devastating—economically and ecologically.

What You Can Do About Spotted Lanternflies Now

If you spot small, polka-dotted black or red insects hopping around your yard, garden, or trees, don’t wait—take action. Call Viking Pest Control for treatments that get spotted lanternfly nymphs under control before they can do damage to your property or spread out to do damage to trees and plants across your entire community. The earlier we respond, the better chance we have of reducing their numbers before they reach the adult stage and cause widespread damage later this year.

Eric Gunner
Viking Pest Control
+1 800-618-2847
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, firmy czy instytucje państwowe.
Ostatnio dodane
komunikaty PR z wybranej przez Ciebie kategorii
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 04:55:04

DXRacer, 전설적인 저격수 kennyS와 손잡고 e스포츠 역사의 새로운 장을 열다

KennyS X DXRACER CollaborationMartian ProKennyS Legend SniperDXRACER— 장인정신으로 클래식을 기리고, 혁신을 통해 미래를 포용하다SEOUL, SOUTH KOREA, June 17, 2025 /EINPresswire.com/ -- [전설적인 동맹: 최고의
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

NEXCOM EBC 370 Powers Autonomous Robotics for Industrial Applications

Highly Efficient, Edge AI Computing Delivered in a Compact New CPUThe EBC 370/EBC 370X is an AI-powered, PC-based controller designed to adapt to the most demanding conditions. Research labs use it as the main control unit for advanced robotics
EIN Newswire BRAK ZDJĘCIA
2025-06-17 | 03:55:06

The End Brain Cancer Initiative Partners with Curis to Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial

The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial REDMOND, WA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Contact: Dellann Elliott Mydland, 425-785-8489, Dellann@EndBrainCancer.org The End Brain Cancer Initiative Partners with Curis to Promote Awareness and Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial The End Brain Cancer Initiative (EBCI) has partnered with Curis to promote awareness and pre-qualify patients for the company’s TakeAim Lymphoma Clinical Trial (CA-4948-101) clinical trial, an open-label, dose escalation and expansion trial of Emavusertib in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/​R PCNSL) (NCT03328078). “We are proud to partner with the End Brain Cancer Initiative to help raise awareness for primary CNS lymphoma (PCNSL), a rare and challenging form of cancer non-Hodgkin lymphoma. Together, we aim to highlight the unmet medical needs of this patient community, provide relevant resources to patients and their care providers, along with increasing awareness of clinical trials,” shared the Chief Medical Officer of Curis Inc, Ahmed Hamdy, MD. “Curis is committed to developing emavusertib for the treatment of PCNSL and broader non-Hodgkin lymphoma indications.” Patients who would like to learn more about this clinical trial and see if they qualify can visit https://endbraincancer.org/curis-therapeutics/ or contact the End Brain Cancer Initiative’s Clinical Research Coordinator and Patient Navigator, Shreya Prakash, at Shreya@EndBrainCancer.org or 425-436-8688. About Curis Curis, located in Lexington, Massachusetts, is a biotechnology company focused on the development of Emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to Emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at https://www.curis.com/. About the End Brain Cancer Initiative To support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services and programs, please visit EndBrainCancer.org The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative or how to sponsor this annual campaign at EndBrainCancer.org. Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org

Kalendarium

Więcej ważnych informacji

Jedynka Newserii

Jedynka Newserii

Kongres Profesjonalistów Public Relations

Ochrona środowiska

Z powodu braku przejrzystego prawa branża recyklingu odkłada inwestycje. Firmy apelują o szybkie wdrożenie przepisów

Branża recyklingu stoi przed wyzwaniami związanymi z wdrożeniem systemu kaucyjnego, systemu rozszerzonej odpowiedzialności producenta i rozporządzenia PPWR. Brakuje jednak odpowiednich przepisów dostosowujących polskie prawo i realia do unijnych regulacji. W efekcie utrzymującej się niepewności prawnej między 2018 a 2023 rokiem co trzeci zakład recyklingu zamknął działalność. Wiele firm odkłada inwestycje, czekając na uregulowanie rynku. Podobna niepewność dotyczy też producentów opakowań. 

Transport

Testowanie pojazdów zautomatyzowanych wkrótce będzie możliwe. To odpowiedź na postulaty przedsiębiorców

Kończą się prace nad przepisami, które mają usprawnić prace badawcze nad pojazdami zautomatyzowanymi. Ma to być odpowiedź na postulaty przedsiębiorców, którzy wskazywali na potrzebę pilnej zmiany przepisów w zakresie testowania pojazdów autonomicznych. Obecne regulacje nie sprzyjają postępowi technologicznemu i rozwoju autonomiczności pojazdów, o czym świadczy bardzo niewielka liczba wydanych uprawnień do ich prowadzenia.

Firma

Przedsiębiorcom coraz bardziej doskwiera niestabilność i skomplikowanie przepisów podatkowych. Problemem są też niejasne ich interpretacje

Polscy przedsiębiorcy często negatywnie oceniają jakość przepisów podatkowych – wynika z raportu „Przedsiębiorcy pod lupą fiskusa 2025” przygotowanego przez firmę doradztwa podatkowego MDDP we współpracy z Konfederacją Lewiatan. Ich niepokój budzą niejednolite interpretacje przepisów i niepewność prawa podatkowego, które cały czas jest modyfikowane. Wśród kluczowych zmian w obszarze podatków, które będą dotyczyć praktycznie wszystkich przedsiębiorców, są m.in. wprowadzenie Krajowego Systemu e-Faktur czy zmiany w podatku od nieruchomości.

Partner serwisu

Instytut Monitorowania Mediów

Szkolenia

Akademia Newserii

Akademia Newserii to projekt, w ramach którego najlepsi polscy dziennikarze biznesowi, giełdowi oraz lifestylowi, a  także szkoleniowcy z wieloletnim doświadczeniem dzielą się swoją wiedzą nt. pracy z mediami.